^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TCRT-ESO-A2
i
Other names: TCRT-ESO-A2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Axis Therap, Guangzhou Xiangxue Pharma, PharmaEssentia
Drug class:
T-cell stimulant, NY ESO 1 inhibitor
Related drugs:
2years
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=0, Withdrawn, Athenex, Inc. | N=48 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01 • CTAG1B expression
|
TCRT-ESO-A2
almost3years
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=48, Recruiting, Athenex, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B)
|
HLA-A*02:01 • CTAG1B expression
|
TCRT-ESO-A2
over3years
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Athenex, Inc.
Clinical • New P1 trial
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
TCRT-ESO-A2
Share via
